Literature DB >> 11316518

Serine/threonine kinases as molecular targets of antidepressants: implications for pharmacological treatment and pathophysiology of affective disorders.

M Popoli1, S Mori, N Brunello, J Perez, M Gennarelli, G Racagni.   

Abstract

It is currently a widely accepted opinion that adaptive, plastic changes in the molecular and cellular components of neuronal signaling systems correlate with the effects on mood and cognition observed after long-term treatment with antidepressant drugs. Protein phosphorylation represents a key step for most signaling systems, and it is involved in the regulation of virtually all cellular functions. Two serine/threonine kinases, Ca2+ /calmodulin-dependent protein kinase II and cyclic AMP-dependent protein kinase, have been shown to be activated in the brain following antidepressant treatment. The changes in kinase activity are mirrored by changes in the phosphorylation of selected protein substrates in subcellular compartments (presynaptic terminals and microtubules), which, in turn, may contribute to the modulation of synaptic transmission observed with antidepressants. The molecular consequences of protein kinase activation may account for some of the alterations in neural function induced by antidepressants, and may suggest novel possible strategies of pharmacological intervention.

Mesh:

Substances:

Year:  2001        PMID: 11316518     DOI: 10.1016/s0163-7258(00)00108-x

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  8 in total

1.  Ketamine regulates the presynaptic release machinery in the hippocampus.

Authors:  Heidi Kaastrup Müller; Gregers Wegener; Nico Liebenberg; Carlos A Zarate; Maurizio Popoli; Betina Elfving
Journal:  J Psychiatr Res       Date:  2013-03-30       Impact factor: 4.791

2.  Glutamate receptors as targets of protein kinase C in the pathophysiology and treatment of animal models of mania.

Authors:  Steven T Szabo; Rodrigo Machado-Vieira; Peixiong Yuan; Yun Wang; Yanling Wei; Cynthia Falke; Chiara Cirelli; Giulio Tononi; Husseini K Manji; Jing Du
Journal:  Neuropharmacology       Date:  2008-08-22       Impact factor: 5.250

3.  Norepinephrine-mediated regulation of 5HT1 receptor functioning in human platelets.

Authors:  M L Trincavelli; S Cuboni; M Montali; S Santaguida; A Lucacchini; C Martini
Journal:  Neurochem Res       Date:  2008-02-13       Impact factor: 3.996

4.  Behavioural and biochemical changes in maternally separated Sprague-Dawley rats exposed to restraint stress.

Authors:  P J van Zyl; J J Dimatelis; V A Russell
Journal:  Metab Brain Dis       Date:  2015-11-11       Impact factor: 3.584

Review 5.  The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders.

Authors:  Kinga Sałaciak; Aleksandra Koszałka; Elżbieta Żmudzka; Karolina Pytka
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

6.  Time-dependent activation of MAPK/Erk1/2 and Akt/GSK3 cascades: modulation by agomelatine.

Authors:  Laura Musazzi; Mara Seguini; Alessandra Mallei; Giulia Treccani; Mariagrazia Pelizzari; Paolo Tornese; Giorgio Racagni; Daniela Tardito
Journal:  BMC Neurosci       Date:  2014-10-21       Impact factor: 3.288

7.  Chronic treatment with agomelatine or venlafaxine reduces depolarization-evoked glutamate release from hippocampal synaptosomes.

Authors:  Marco Milanese; Daniela Tardito; Laura Musazzi; Giulia Treccani; Alessandra Mallei; Tiziana Bonifacino; Cecilia Gabriel; Elisabeth Mocaer; Giorgio Racagni; Maurizio Popoli; Giambattista Bonanno
Journal:  BMC Neurosci       Date:  2013-07-29       Impact factor: 3.288

8.  Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of "paradoxical" antidepressant responses in young persons.

Authors:  Emily A Karanges; Mohammed A Kashem; Ranjana Sarker; Eakhlas U Ahmed; Selina Ahmed; Petra S Van Nieuwenhuijzen; Andrew H Kemp; Iain S McGregor
Journal:  Front Pharmacol       Date:  2013-07-08       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.